Mutations in FBXO11 have also been identified in 10–20% of Burkitt’s lymphoma and cases of de novo AML, suggesting that it may have a broad role as a tumor suppressor in hematologic malignancies11,12. This evidence concerns the gene FBXO11 and acute myeloid leukemia.